Loading...
XNAS
SPRC
Market cap315kUSD
Jul 09, Last price  
5.45USD
1D
-0.73%
1Q
73.02%
IPO
-99.98%
Name

Scisparc Ltd

Chart & Performance

D1W1MN
XNAS:SPRC chart
P/E
—
P/S
0.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-2.47%
Rev. gr., 5y
9.25%
Revenues
856k
-34.46%
00001,650,732000000487,000838,000498,000550,0001,069,0001,347,0002,879,0001,306,000856,000
Net income
-12m
L+93.81%
-1,721,962-4,883,332-3,640,927-2,565,718-3,550,105-3,718,643059,440000-6,244,000-8,523,000-5,362,000-3,507,000-5,801,000-2,592,000-5,122,000-6,284,000-12,179,000
CFO
-4m
L-18.95%
-1,460,964-3,175,321-3,224,438-1,909,075-3,771,417-3,783,20100000-4,579,000-7,132,000-4,696,000-4,307,000-5,061,000-7,917,000-5,887,000-5,104,000-4,137,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
URL
https://scisparc.com/
IPO date
Dec 22, 2021
Employees
3
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT